42 patents
Utility
EZH2 Inhibition Therapies for the Treatment of Androgen Receptor Mutated Prostate Cancers
28 Dec 23
Provided herein are methods of treating prostate cancer having at least one pathogenic AR mutation using 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3- yl)methyl)benzo[d][1,3]dioxole-5-carboxamide, or a pharmaceutically acceptable salt thereof, alone or in combination with a therapeutically effective amount of an androgen receptor signaling inhibitor (ARSI) such as enzalutamide.
William D. Bradley, Jike Cui, Kaiming Sun, Patrick Trojer, Jing Wang, Rentian Wu
Filed: 18 Nov 21
Utility
2-((4S)-6-(4-CHLOROPHENYL)-1-METHYL-4H-BENZO[C]ISOXAZOLO[4,5-E]AZEPIN-4-YL)ACETAMIDE for Treating Thrombocythemia
28 Sep 23
The present disclosure relates to the use of 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide, and pharmaceutically acceptable salts thereof, for treating thrombocythemia.
Adrian Senderowicz
Filed: 3 Aug 21
Utility
Substituted Benzamides As Modulators of TREX1
27 Jul 23
Mary-Margaret Zablocki, Kennedy Taveras, Jonathan E. Wilson, Aaron Coffin, Julian R. Levell, Aravind Prasad Medikonda
Filed: 27 May 21
Utility
Methods of Treating Myeloproliferative Disorders
23 Feb 23
The present disclosure relates to the use of 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide, and pharmaceutically acceptable salts thereof, for treating myelofibrosis.
Adrian Senderowicz, Michael Cooper
Filed: 1 Apr 22
Utility
LSD1 inhibitors and medical uses thereof
10 Jan 23
Francois Brucelle, Victor S. Gehling, Avinash Khanna
Filed: 27 Apr 21
Utility
Compounds for Use In Treating Neurological Disorders
20 Oct 22
Francois Brucelle, Julian R. Levell, Jonathan E. Wilson
Filed: 29 Jul 20
Utility
Modulators of TREX1
6 Oct 22
Avinash Khanna, Jonathan E. Wilson, Mary-Margaret Zablocki
Filed: 1 May 20
Utility
Modulators of methyl modifying enzymes, compositions and uses thereof
4 Oct 22
Jehrod B. Brenneman, Alexandre Côté, Victor S. Gehling, Avinash Khanna, Julian R. Levell, Ludivine Moine
Filed: 8 Nov 18
Utility
Modulators of TREX1
15 Sep 22
Avinash Khanna, Jonathan E. Wilson
Filed: 22 Jul 20
Utility
EZH2 Inhibition In Combination Therapies for the Treatment of Cancers
18 Aug 22
Provided herein are methods for treating advanced relapsed solid tumors using 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2, 4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide; or a pharmaceutically acceptable salt thereof.
William D. Bradley
Filed: 23 Jul 20
Utility
P300/CBP hat inhibitors
16 Aug 22
Jonathan E. Wilson, Julian R. Levell
Filed: 15 Feb 19
Utility
Crystalline Forms of 7-CHLORO-2-(4-(3-METHOXYAZETIDIN-1-YL)CYCLOHEXYL)-2,4-DIMETHYL-N-((6-METHYL-4-(METHYLTHIO)-2-OXO-1,2-DIHYDROPYRIDIN-3-YL)METHYL)BENZO[D][1,3]DIOXOLE-5-CARBOXAMIDE
11 Aug 22
The present disclosure relates to a crystalline Form 1 of 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-di -methyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d] [1,3]dioxole-5-carboxamide, which is useful as modulators the activity of histone methyl modifying enzymes.
Alamelu Banda, Victor S. Gehling
Filed: 23 Jul 20
Utility
P300/CBP Hat Inhibitors and Methods for Their Use
5 May 22
Jonathan E. Wilson
Filed: 26 Feb 20
Utility
Therapeutic Compounds and Uses Thereof
28 Apr 22
Patrick Cyr, Sarah Bronner, F. Anthony Romero, Steven Magnuson, Vickie Hsiao-Wei Tsui, Jeremy M. Murray, John Wai, Kwong Wah Lai, Fei Wang, Kevin X. Chen
Filed: 6 Jan 22
Utility
LSD1 Inhibitors and Medical Uses Thereof
17 Mar 22
Provided are novel compounds of Formula (I or Ia′): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with LSD1.
Francois Brucelle, Victor S. Gehling, Avinash Khanna
Filed: 27 Apr 21
Utility
P300/CBP HAT inhibitors
15 Mar 22
Jonathan E. Wilson, Francois Brucelle, Julian R. Levell
Filed: 15 Feb 19
Utility
Modulators of methyl modifying enzymes, compositions and uses thereof
15 Mar 22
Alexandre Côté, Victor S. Gehling, Avinash Khanna, Ludivine Moine, Jacob I. Stuckey
Filed: 23 Apr 20
Utility
Therapeutic compounds and uses thereof
15 Feb 22
Patrick Cyr, Sarah Bronner, F. Anthony Romero, Steven Magnuson, Vickie Hsiao-Wei Tsui, Jeremy M. Murray, John Wai, Kwong Wah Lai, Fei Wang, Kevin X. Chen
Filed: 21 Nov 18
Utility
Modulators of TREX1
20 Jan 22
Anna Gardberg, Victor S. Gehling, Avinash Khanna, Julian R. Levell, Jonathan E. Wilson, Kennedy Taveras
Filed: 6 Dec 19
Utility
Therapeutic compounds and uses thereof
9 Nov 21
Patrick Cyr, Sarah Bronner, F. Anthony Romero, Steven Magnuson, Vickie Hsiao-Wei Tsui, John Wai, Kwong Wah Lai, Fei Wang
Filed: 28 May 20